Navigation Links
CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
Date:1/18/2011

on Earp III, M.D., Professor and Director of Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill School of Medicine.  "While still early stage, I look forward to further research into the effect CFAK-C4 may have on solid tumors."

About Focal Adhesion Kinase (FAK)Focal adhesion Kinase (FAK) is substantially over-expressed in many solid tumors. FAK operates by placing itself at the contact points between tumor cells and the extra cellular matrix that surrounds them. Studies by CureFAKtor and others found that in this role, FAK is an important facilitator for signals that cause tumor cells to survive, grow, and produce new blood vessels to sustain growth and travel to distant places within the body where they may establish new tumor sites. It also cocoons the tumor cells to protect them from the body's natural signaling mechanisms that would cause deviant tumor cells to be eliminated. In a similar fashion, FAK protects tumors from chemotherapeutic drugs and radiation, allowing the tumor cells to resist these therapies.

About CureFAKtor PharmaceuticalsCureFAKtor Pharmaceuticals is a biopharmaceutical company focused on the research and development of Focal Adhesion Kinase therapies to prevent or treat cancer. CureFAKtor's investigational and combination therapy products target pancreatic, breast, colon, melanoma, lung and brain oncology disorders. CureFAKtor research is conducted at the Roswell Park Cancer Institute. Additional information about the company may be found at www.curefaktor.com Forward-Looking Safe Harbor Statement:This press release contains forward-looking statements for CureFAKtor Pharmaceuticals that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts
'/>"/>

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
2. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
3. Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote
4. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
5. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
6. Reportlinker Adds OTC Pharmaceuticals: Global Industry Almanac
7. ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing
8. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
9. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
10. Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
11. Optimer Pharmaceuticals Announces Key Additions to Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis ... results from two pre-clinical studies that,support the ... rich in,cysteine) expression in cancer and Abraxis' ... Association for Cancer Research (AACR) Annual Meeting ...
... Transurethral Resection,is Well Tolerated in Phase 2b Bladder ... --,Spectrum Pharmaceuticals, Inc., today announced results of a ... and the,presentation of preclinical data of SPI (IRL)-1620 ... Association of Cancer,Research, held at the Los Angeles ...
Cached Medicine Technology:Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 2Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 3Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 4Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 5Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 2Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 3Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 4Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 5Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 6Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 7Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 8
(Date:4/17/2014)... Calif., April 17, 2014 By discovering a new ... after a stroke, researchers at UC Irvine and the ... that may limit or prevent stroke-induced brain damage. , ... fourth-leading cause of death and primary reason for disability ... in a stroke and lets blood-borne material into the ...
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
(Date:4/17/2014)... online has the potential to ward off depression among ... research published online in The Journals of ... . In the article " Internet Use and Depression ... Longitudinal Analysis ," the authors report that Internet use ... percent among their study sample. , Late-life depression ...
(Date:4/17/2014)... April 2014) Population Council scientists and their partners have ... and can prevent the transmission of multiple sexually transmitted ... animals: HIV, herpes simplex virus 2 (HSV-2), and human ... data that the gel is effective against multiple strains ... the vagina against all three viruses of at least ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... 25, 2007) George Mason University professor of ... grant from the National Institutes of Health to ... Alzheimer,s disease. His program, "Apolipoprotein, Attention and Alzheimer,s ... and older adults for four years using cognitive, ...
... The Partnership to,Fight Chronic Disease (PFCD) announced today ... all 2008 presidential candidates to address the,country,s chronic disease ... reform will be the most important domestic issue in ... and,Professor and Chair of the Rollins School of Public ...
... National Marrow Donor Program,s Office of Patient Advocacy receives ... to help cancer survivors like Ryan, MINNEAPOLIS, Sept. 25 ... most of his life. Diagnosed with acute,myelogenous leukemia at just ... marrow or cord blood transplant to survive. Ryan received ...
... the, importance of staying active and eating healthy ... Calif., Sept. 25 Blue Cross of,California, collaborating ... Sports, is launching a 14-week statewide mobile,outreach campaign ... to make,healthy lifestyle choices now and in the ...
... Natural Cottage Cheese and NBC 10 Seek the Next Local ... in This Year,s Healthy Lifestyle ... massage,therapist, a 35-year-old administrative assistant, a 41-year-old comedian,and computer help ... teacher have in common? They,re all contestants in,"The Friendship All ...
... results from the randomized, double -blind,placebo -controlled, Phase ... of ZD4054 - a,specific endothelin A (ETA) receptor ... European,Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona). ... in development for the treatment of men with ...
Cached Medicine News:Health News:George Mason University professor receives $2.6 million NIH grant to study Alzheimer's disease 2Health News:Partnership to Fight Chronic Disease Announces 'Ideas for Change' in Health Care 2Health News:Partnership to Fight Chronic Disease Announces 'Ideas for Change' in Health Care 3Health News:Young Twin Cities Boy Shows There is Life After Cancer 2Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 2Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 3Health News:Five Local Residents Vie to be Philadelphia's Biggest 2007 'Local Loser' 2Health News:Five Local Residents Vie to be Philadelphia's Biggest 2007 'Local Loser' 3Health News:Five Local Residents Vie to be Philadelphia's Biggest 2007 'Local Loser' 4Health News:Survival data presented from phase II study of hormone-resistant prostate cancer patients 2
... known as bone Gla protein, is a ... a major component of the noncollagenous bone ... in bone, with a small amount produced ... [1]. During bone formation, newly synthesized osteocalcin ...
... Binding Protein-1 (IGFBP-1) is a phosphoprotein, produced ... and modulates the bioactivity of IGF-I and ... not been completely defined, but the nature ... be involved in glucose regulation and IGF-mediated ...
... factor binding protein 4 (IGFBP-4) is a 24 ... actions of IGF-I and IGF-II. It is also ... weight of 28 kDa. IGFBP-4 has been identified ... numerous cell types, including fibroblasts, neuroblastoma, prostate and ...
... Androstenedione, produced in the adrenal gland and ... testosterone and estrone, both of which may ... relatively weak androgenic activity, estimated at ~(less ... [1]. However, serum androstenedione levels often exceed ...
Medicine Products: